Categories AlphaGraphs, Earnings, LATEST, Technology
Cognex’s revenue and profit declines in Q3, provides weak outlook
As expected, Cognex (CGNX) reported a decline in the bottom and top line numbers for the third quarter sending the shares into the negative territory during the extended market hours on Monday.
The maker of barcode readers’ revenue dropped 13% year-over-year to $232 million and non-GAAP profit per share slumped 24% to 39 cents in the recently ended quarter. GAAP EPS dropped 21% to 45 cents.
For the fourth quarter of 2018, Cognex expects revenue to be between $180 million and $190 million. At the mid-point, this outlook is lower than the company’s long-term growth target due to both the slower spending by customers in China and a lingering headwind from last year’s high level of investment by the large OLED display and smartphone manufacturers.
“While we are pleased with our Q3-18 results, slower spending trends that we are experiencing in China have reduced our revenue outlook for Q4-18,” said CEO Robert Willett.
Research, Development & Engineering expenses increased 14% from the prior year, due to Cognex’s investment in engineering resources for new product development. Selling, General & Administrative expenses increased 8% due to continued investments in sales resources as well as higher commissions and travel expenses.
Cognex increased its quarterly cash dividend by 11% to $0.05 per share, payable on November 30, 2018, to all shareholders of record as of November 16, 2018. Also, the Board authorized the repurchase of up to $200 million of Cognex stock in open market transactions.
Shares of Cognex, which plunged to a 52-week low ($39.00) during Monday’s regular trading session, closed at $39.61, down 3.95%. After the earnings announcement, the stock continued its poor performance by tanking another 10% in the extended hours of trading.
Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on